Thrombosis Research
Volume 126, Issue 2 , Pages 124-129, August 2010

Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats

  • Noriko Konishi

      Affiliations

    • Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd., Osaka, Japan
  • ,
  • Katsuhiko Hiroe

      Affiliations

    • Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd., Osaka, Japan
  • ,
  • Masaki Kawamura

      Affiliations

    • Takeda Global Research & Development Center, Inc., IL, USA
    • Corresponding Author InformationCorresponding author. Takeda Global Research & Development Center, Inc., 675 North Field Drive, Lake Forest, IL, 60045 USA. Tel.: +1 847 582 3621; fax: +1 224 554 7945.

Received 11 December 2009; received in revised form 19 March 2010; accepted 7 April 2010. published online 11 May 2010.

Abstract 

Introduction

Activated platelets facilitate blood coagulation by providing factor V and a procoagulant surface for prothrombinase. Here, we investigated the potential synergy of a potent factor Xa/prothrombinase inhibitor, TAK-442, plus aspirin or clopidogrel in preventing arterial thrombosis and whole blood coagulation.

Methods

Thrombus formation was initiated by FeCl3-induced rat carotid injury. Bleeding time was evaluated with the rat tail transection model. Whole blood coagulation was assessed by thromboelastographic examination (TEG) for which blood obtained from control, aspirin-, or clopidogrel-treated rats was transferred to a TEG analyzer containing, collagen or adenosine diphosphate (ADP), and TAK-442 or vehicle.

Results

TAK-442 (3mg/kg, po), aspirin (100mg/kg, po) or clopidogrel (3mg/kg, po) alone had no significant effect on thrombus formation, whereas the combination of TAK-442 with aspirin and clopidogrel remarkably prolonged the time to thrombus formation without additional significant prolongation of bleeding time. TEG demonstrated that the onset of collagen-induced blood coagulation were slightly longer in aspirin-treated rats than control; however, when the blood from aspirin-treated rats was subsequently treated in vitro with 100nM TAK-442, the onset of clotting was significantly prolonged. In contrast, only marginal prolongation was observed with TAK-442 treatment of blood from control animals. The onset time of ADP-induced blood coagulation was slightly longer in clopidogrel-treated rats compared with control, and it was further extended by TAK-442 treatment.

Conclusion

These results demonstrate that blood coagulation can be markedly delayed by the addition of TAK-442 to antiplatelets treatment which could contribute to synergistic antithrombotic efficacy in these settings.

Abbreviations: FXa, factor Xa, TEG, thromboelastographic/thromboelastograph, ADP, adenosine diphosphate, PT, prothrombin time, APTT, activated partial thromboplastin time, TTO, time to occlusive thrombus formation, PRP, platelet rich plasma, PPP, platelet poor plasma

Keywords: TAK-442, Direct factor Xa inhibitor, Aspirin, Clopidogrel, Thromboelastography, Arterial thrombosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-3848(10)00230-6

doi:10.1016/j.thromres.2010.04.005

Thrombosis Research
Volume 126, Issue 2 , Pages 124-129, August 2010